Amgen has signed a deal worth up to US$1.5 B with CytomX to co-develop new cancer immunotherapies employing CytomX’s Probody™ T-cell engaging bispecific programme against the epidermal growth factor receptor (EGFR) – a target that is expressed on multiple cancer types. This is the second major deal signed by CytomX in the same year; the first was with Bristol-Myers Squibb (BMS) which expanded its collaboration with CytomX to develop Probodies for numerous oncology and non-oncology targets.